Poseida Therapeutics snags $30.5 mln Series B
San Diego-based Poseida Therapeutics Inc, which translates gene engineering technologies into cell therapies, has raised $30.5 million in Series B financing. Longitude Capital led the round with participation from other investors that included Vivo Capital, the Tavistock Group and Malin Corporation plc. In conjunction with the financing, Dr. David Hirsch, a managing director at Longitude Capital, has joined Poseida’s board of directors.
4 April 2018•1 min read
